Violin Jonathan 4

What Happened Jonathan Violin, a director of Crescent BioPharma (CBIO), was granted a derivative award on 2026-06-02 giving him the right to purchase 11,050 ordinary shares. The Form 4 reports the acquisition as a derivative instrument with an acquisition price of $0.00 (i.e., a grant of an option/award rather than a cash purchase or sale).

Key Details

• Transaction date: 2026-06-02; Filing date: 2026-06-03 (timely filing).
• Transaction type/code: Grant/Award (A) reported as a derivative.
• Quantity: option to purchase 11,050 shares; reported acquisition price: $0.00.
• Vesting: the option vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the issuer's next annual meeting of shareholders, subject to continued service by the reporting person (footnote).
• Shares owned after transaction: not specified in the provided filing.
• No indication of a 10b5-1 plan, tax withholding, or cashless exercise in this filing.

Context This was a compensation-style award (an option/derivative that vests over time), not an outright purchase or sale of stock. Such grants give the insider a future right to buy shares if vesting conditions are met; they do not represent immediate ownership or liquidity unless and until exercised.